Navigation Links
U.S. Government Awards $15 Million Grant to GeoVax Labs' HIV/AIDS Vaccine Program
Date:9/26/2007

ATLANTA, Sept. 26 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta based biotechnology company, announced receipt of an estimated $15,000,000 Integrated Preclinical/Clinical AIDS Vaccine Development [IPCAVD] Grant to support its HIV/AIDS vaccine program.

This large Grant was awarded by the National Institutes of Health-National Institute of Allergy & Infectious Disease [NIH-NIAID], an agency of the U.S. Government. Funding commences October 2007.

Only meritorious HIV/AIDS prevention vaccine candidates are considered to receive an IPCAVD award. Candidate companies are highly scrutinized and must supply substantial positive AIDS vaccine data to support their application. IPCAVD grants are awarded on a competitive basis and are designed to support later stage vaccine research, development and human trials.

GeoVax will utilize this funding to further its HIV/AIDS vaccine development, optimization, production and human clinical trial testing including Phase 2 human clinical trials planned for 2008.

Dr. Harriet Robinson, Chief Scientific Advisor for GeoVax, guided development of the IPCAVD proposal and will lead a major part of its related studies. Dr. Robinson stated, "This grant will allow GeoVax to move forward our AIDS vaccine evaluation program more efficiently and more rapidly."

"Our selection as a grant recipient is a validation of our vaccine technology, scientific program, success in human trials to date and future strategies," said GeoVax President/CEO, Don Hildebrand. "This $15 million in funding will support additional AIDS vaccine studies as well as expansion of our scientific team at GeoVax."

About GeoVax Labs, Inc. (http://www.geovax.com)

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is protected by 20 filed patent applications and issued patents.

GeoVax HIV/AIDS vaccines are designed to prevent development of Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, by vaccinating individuals prior to infection with the AIDS virus. In addition, GeoVax AIDS vaccines may be effective as therapeutics (treatment of people infected with AIDS virus). Studies evaluating these vaccines in already HIV/AIDS infected individuals are being planned.

GeoVax DNA and Recombinant MVA HIV/AIDS vaccines:

-- Use DNA vaccines to "prime" immune responses and MVA vaccines to

"boost" immune responses against the AIDS virus

-- Vaccinate against more than 50% of AIDS virus components and can not

cause AIDS

-- Protected 22 of 23 (96%) non-human primates for over 3 1/2 years

post-infection with an AIDS inducing virus. Five of six non-vaccinated

controls died of AIDS within the 1st year of infection. These trials

used a prototype SIV/HIV vaccine for the HIV vaccine that is being

advanced in human trials

-- Are manufactured & tested under GMP/GLP - EMEA (EU) and FDA guidelines

-- Satisfactorily completed earlier DNA HIV/AIDS vaccine Phase 1 human

trial

-- Are currently being tested in 4 Human Trials. Two started in 2006, two

in summer 2007

-- Have been demonstrated safe to date in human trials

-- Are demonstrating positive immune responses against HIV in majority of

vaccine recipients

-- Are in planning stage for a larger Phase 2 human trial in 2008

For further information, contact Don Hildebrand or Jennifer Nelms at (404) 727-0971 or visit http://www.geovax.com.

Safe Harbor Statement: All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be determined to be safe for use in humans, GeoVax's vaccines will be effective in preventing AIDS in humans, the vaccines will receive the regulatory approvals necessary to be licensed and marketed, GeoVax can raise the required capital to complete development of its vaccines, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitations, risks detailed in the Company's Securities and Exchange Commission filings and report.


'/>"/>
SOURCE GeoVax Labs, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Digital Government Summit seeks to bridge the digital divide
2. Midwest telecom conference to push government cooperation
3. State IT leaders make Government Technologys top-25 list
4. Human cloning plans get blessing from British government
5. State CIO wants to unify electronic government
6. State CIO discusses IT and government
7. Upcoming technology conferences look at government tech and RFID issues
8. Wisconsin technology companies awarded over $24 million in government funding
9. Muskego Powers Local Governments Web Site and Search Capabilities
10. Wisconsin to Get Serious about E-Government
11. SBIR/STTR Programs: Free Money or an Invitation to Governmental Bureaucracy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... Rolf K. Hoffmann, former senior vice ... University of North Carolina Kenan-Flagler Business School effective June 27. , ... with a focus on the school’s international efforts, leading classes and participating in ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS ... the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, ... proud to add Target to its list of well-respected retailers. This list includes ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
Breaking Biology Technology:
(Date:6/20/2016)... , June 20, 2016 Securus ... justice technology solutions for public safety, investigation, corrections ... the prisons involved, it has secured the final ... (DOC) facilities for Managed Access Systems (MAS) installed. ... additional facilities to be installed by October, 2016. ...
(Date:6/15/2016)... 15, 2016 Transparency Market ... Recognition Market by Application Market - Global Industry Analysis Size ... to the report, the  global gesture recognition market ... and is estimated to grow at a CAGR ... 2024.  Increasing application of gesture recognition ...
(Date:6/9/2016)... Paris Police Prefecture and ... ensure the safety of people and operations in several locations ... Teleste, an international technology group specialised in broadband ... its video security solution will be utilised by ... across the country. The system roll-out is scheduled for the ...
Breaking Biology News(10 mins):